Kristina Sonnevi
Huddinge, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 14, 2026
Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.
Journal: Lancet (London, England)
Published: December 23, 2025
Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.
Journal: NPJ precision oncology
Published: December 17, 2025
A 30-minute intravenous infusion of rituximab is safe and cost-effective (SpeedR).
Journal: Annals of hematology
Published: May 06, 2025
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Journal: Lancet (London, England)
Published: February 18, 2025
Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies.
Journal: British journal of haematology
Published: January 12, 2025
Implementation of standard of care CAR-T-cell treatment for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia in Sweden.
Journal: Leukemia
Published: December 15, 2024
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy.
Journal: Leukemia & lymphoma
Published: December 22, 2023
Last Updated: 09/26/2026